Thrombosis and bleeding in hematological malignancy

Tzu Fei Wang, Avi Leader, Kristen M. Sanfilippo*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Venous (VTE) and arterial (ATE) thromboemboli are a leading cause of morbidity and mortality in patients with cancer. Patients with hematological malignancies are at an exceptionally high risk of both VTE and ATE. This risk varies based on patient- and disease-specific risk factors and can be predicted using risk prediction models for some types of hematological malignancies. Treatment of VTE for patients with hematological malignancies is largely based on randomized control trials that predominately enrolled patients with solid tumors. However, treatment must be balanced with the risk of anticoagulant or antiplatelet therapy in this unique patient population that can have a competing risk of bleeding. In this review, we present the evidence that addresses the risk and prediction of VTE, ATE and bleeding in patients with hematological malignancies and considerations for treatment of these conditions.

Original languageEnglish
Article number101353
JournalBest Practice and Research: Clinical Haematology
Volume35
Issue number1
DOIs
StatePublished - Mar 2022

Funding

FundersFunder number
ACS-IRG
National Heart, Lung, and Blood Institute
Pfizer
Novartis
Sanofi
Bayer Fund
LEO Pharma Research Foundation

    Keywords

    • Arterial thromboembolism
    • Bleeding
    • Cancer
    • Hematological malignancy
    • Risk prediction
    • Venous thromboembolism

    Fingerprint

    Dive into the research topics of 'Thrombosis and bleeding in hematological malignancy'. Together they form a unique fingerprint.

    Cite this